Background Systemic lupus erythematosus (SLE) shows marked heterogeneity in epidemiology across regions and over time.

What have we learned from all randomized controlled trials with new agents added on to standard of care for the treatment of patients with systemic lupus erythematosus (SLE)? While positive studies ...

Background SLE is associated with significant morbidity, especially in the case of renal involvement. Mitochondrial dysfunction plays a significant role in SLE and may be assessed by measuring ...

Artificial intelligence and machine learning applications are emerging as transformative technologies in medicine. With greater access to a diverse range of big datasets, researchers are turning to ...

Diagnosis of SLE is based on clinical manifestations and laboratory findings. Timely diagnosis and treatment are important to control disease activity and prevent organ damage. However, diagnosis is ...

Background The physician global assessment (PGA) is a 3-point visual analog scale assessing lupus disease activity. We implemented a Type II PGA to assess what we have termed Type II SLE symptoms.

Objective SLE is a chronic autoimmune disease with immune complex deposition in various organs, causing inflammation. The Systemic Lupus Erythematosus Disease Activity Index 2000 assesses disease ...

Objective To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), ...

Background In the phase 2 study JAHH (NCT02708095), treatment with baricitinib, an oral selective Janus kinase 1/2 inhibitor approved for the treatment of rheumatoid arthritis, resulted in significant ...

Objectives Our current understanding of the genetic architecture of childhood-onset SLE (cSLE) is limited by a dearth of comprehensive genomic studies in cSLE. We have quantified the number of known ...

Objective To describe treatment patterns and the economic burden of cutaneous lupus erythematosus (CLE) using data from a large, commercial insurance database in the United States. Existing data are ...

Objectives Systemic lupus erythematosus (SLE) is a chronic, immune-mediated disease that can affect multiple organ systems, causing debilitating symptoms, organ damage and impaired quality of life.